Evidence map›Paper›PMID 35153783›Full record

ArticleFrontiers in pharmacology2022

Nrf2 Signaling Pathway Mediates the Protective Effects of Daphnetin Against D-Galactose Induced-Premature Ovarian Failure.

Mengwen Zhang, Xiaowei Yu, Danjie Li, Ning Ma, Zhentong Wei, Xinxin Ci, Songling Zhang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Oxidative Stress andInternational journal of molecular sciences · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mengwen ZhangDepartment of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun, China.
Xiaowei YuDepartment of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun, China.
Danjie LiDepartment of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun, China.
Ning MaDepartment of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun, China.
Zhentong WeiDepartment of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun, China.
Xinxin CiInstitute of Translational Medicine, The First Hospital of Jilin University, Changchun, China.
Songling ZhangDepartment of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun, China.
First Hospital of Jilin University · CNJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxidative damage can lead to severe ovarian dysfunctions and even premature ovarian failure. Nrf2, a significant transcription factor that regulates the oxidative stress response of cells, declines with age. Daphnetin, as a kind of natural Chinese herbal medicine, can activate Nrf2 and further promote the antioxidant defense of cells. However, whether Daphnetin treatment can protect ovary from premature ovarian failure and the specific mechanism involved are not understood. This study aimed to investigate the protective function of Daphnetin against the ovarian aging induced by D-galactose in wild-type and Nrf2

Indexed as

daphentinNLRP3Nrf2premature ovarian failureTxnip

Identifiers

PMID35153783
PMCPMC8832979
OpenAlexW4213338550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.